PBA
CYTK icon

Paradigm Biocapital Advisors’s Cytokinetics CYTK Stock Holding History

Paradigm Biocapital Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$97.6M Buy
+1,480,857
New +$94.1M 1.99% 17
2025
Q2 		– Sell
-858,664
Closed -$34.5M – 31
2025
Q1 		$34.5M Buy
+858,664
New +$39.5M 1.58% 16

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Paradigm Biocapital Advisors's CYTK Position: Q1 2026 in Review

Paradigm Biocapital Advisors opened a new position in Cytokinetics (CYTK) in Q1 2026: 1,480,857 shares worth $97.6M. The stake represents 1.99% of the portfolio and ranks #17 among its holdings. This is a return to the name: Paradigm Biocapital Advisors previously reported a position in CYTK as recently as Q1 2025.

Paradigm Biocapital Advisors first reported a position in CYTK in Q1 2025 and has held it in 2 quarters since. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Paradigm Biocapital Advisors held 1,480,857 shares of Cytokinetics worth $97.6M as of Q1 2026.
  • Cytokinetics was a new Paradigm Biocapital Advisors position in Q1 2026.
  • Cytokinetics made up 1.99% of Paradigm Biocapital Advisors's portfolio in Q1 2026, its #17 holding.
  • Paradigm Biocapital Advisors first reported a position in Cytokinetics in Q1 2025 and has held it in 2 quarters since.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Paradigm Biocapital Advisors's 13F filing for Q1 2026, filed 15 May 2026.